Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 14/20 | 0.48 |
| ▸ | F9 | P00740 | 5/20 | 0.48 |
| ▸ | F11 | P03951 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883032 | 0.89 | F7 (0.43) | F7F9F11F10PLAU | |
| SCHEMBL4887203 | 0.88 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL14294292 | 0.83 | NR1H4 (0.40) | F7F10F2NR1H4EPHX2 | |
| SCHEMBL4887599 | 0.82 | F7 (0.46) | F7F9F11F10PLAU | |
| SCHEMBL4884621 | 0.81 | MAPK14 (0.53) | F7F9F11F10PLAU | |
| SCHEMBL4885084 | 0.77 | MAPK14 (0.46) | F7F9F11F10PLAU | |
| SCHEMBL4877481 | 0.76 | MAPK14 (0.43) | F7F9F11F10PLAU | |
| SCHEMBL14269627 | 0.76 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL4882979 | 0.75 | CNR2 (0.53) | F7F9F11F10PLAU | |
| SCHEMBL14294164 | 0.75 | MAPK14 (0.44) | F7F9F11F10PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| EP-1805132-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006110173-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | MAPK1, MAPKAPK2, MAPK6 | F7 4712/4885F9 4810/4885F11 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.